Sancilio & Company, Inc., a pharmaceutical product development and manufacturing company based in Riviera Beach, FL, was granted Orphan Drug Designation by the U.S. Food and Drug Administration for its omega-3 fatty acid product, docosahexaenoic acid (DHA) for the treatment of sickle cell disease (SCD). SCD is a rare genetic disease characterized by abnormality in hemoglobin proteins. Currently, there is no effective treatment for this rare disease. Research has shown that the levels of antiaggregatory, antiinflammatory, and vasodilatory omega-3 fatty acids, DHA and EPA (eicosapentaenoic acid), are significantly reduced in SCD patients and small clinical trials with these two fatty acids have shown promising results in SCD patients. Sancilio has developed a proprietary formulation and manufacturing techniques called Advanced Lipid TechnologyTM (ALTTM) that increases the bioavailability of these insoluble omega-3 fatty acids.
Amer. J. Clinical Nutr., 97: 37-44, 2013. PMID: 23193009